



Agnès Cadet-Taïrou
Magali Martinez

French Monitoring
Center for Drugs and
Drugs Addiction

Focal point of EMCDDA
network (REITOX)

The French prioritization process of spreading New Psychoactive Substances

UNODC-WHO expert consultations
on New Psychoactive substances
Vienna, 9-11 December



To quote this presentation :


Agnès Cadet-Taïrou, Magali Martinez, *The French prioritization process of spreading New Psychoactive Substances*, UNODC-WHO Expert consultations on New Psychoactive substances, Vienne 9-11 December 2014.

Pour citer cette présentation :

Agnès Cadet-Taïrou, Magali Martinez, *Le processus français de priorisation des Nouveaux Produits de Synthèse en diffusion*, Consultation par l'ONUCD et l'OMS d'experts nationaux à propos des NPS , Vienne 9-11 Décembre 2014.

A French overview

Number of Synthetic NPS detected in France by year of first detection 2000-2008



Current actual prioritization in France

■ Two main purposes for prioritization

- Assessment and classification
- Prevention and harm reduction

■ For both, 1st criteria should be related harm, but :

- Paucity of reporting of serious adverse effects
- When reported, frequent lack of identification by toxicological analysis
- Weakness of data sharing (and knowledge) process between institutions

■ Consequences

- No real prioritization until today:
 - Generic classification for cathinones
 - Others assessed according to international evidence of harm produced
- A need to extend the range of criteria or data sources for prioritization
- A need to improve NPS related harm monitoring (toxicovigilance system)
- A need to centralize information at national level


Ongoing projects

- European project I-TREND that includes elaboration of national and common NPS Top list



- National project : Measure 38 of the French government plan against drugs that partly aims to increase NPS identification in emergency rooms
- Revitalizing partnerships between national Institutions to gather information from all partners

A glance at the I-TREND project



Building a classification

WS piloted by LJMU*

■ 1st step: 2013

- Using easily available sources:
 - Seizures: partly biased (no random)
 - Toxicovigilance: far from exhaustive, just a list without precision
 - SINTES (EWS) not exhaustive and biased
- Expert discussions (qualitative data) to finalize each national Top list
- Elaborating an aggregated (5 countries) Top list

■ 2nd Step: 2014, 1st semester

- Adding
 - Online Forum monitoring
 - Online survey in NPS users
- Elaborating each national top List national




*Liverpool John Moores University



www.ofdt.fr

Information sources



Lists by source

National Agency for Medicines	Scientific Police	Custom services	French EWS SINTES	Forums monitoring	Last used NPS
Toxicovigilance	Seizures	Seizures	Substances collected from users	Substances online popularity	Users answers to online survey
TA / Not ranked	TA /Ranked	TA /Ranked	TA /Ranked	NoTA / Ranked	NoTA / Ranked
25C-NBOMe	Methoxetamine	x-MEC	Methoxetamine	3-MMC	Methoxetamine
25I-NBOMe	5F-AKB-48	4-FA	3-MMC	Methylone	Ethylphenidate
2C-C	ALPHA-PVP	DMT	2C-B	Ethylphenidate	2C-B
2C-D	2C-E	Methylone	2C-P	4-MEC	2C-P
2C-E	4-MEC	3-MMC	25C-NBOMe	Methoxetamine	3MMC
2C-I	MDPV	x-EAPB	4-MEC	BK-2CB	Mephedrone
2C-P	THJ 018	4-MEC	ALPHA-PVP	MDPV	4-MEC
3-MMC	THJ 2201	Ethylphenidate	DOC	Synthacaine	25i-nbome
4-MEC	25C-NBOMe	MPA	Ethylphenidate	MPA	2C-D
6-APB	25H-NBOMe	JWH-073	MDPV	Mephedrone	25c-NBOME
ALPHA-PVP	2C-D	2C-B	25B-NBOMe	6-APB	2C-E
Ethylphenidate	2C-P	Éthylcathinone	25H-NBOMe	AMT	LSZ
MDPV	AB FUBINACA	Harmine	2C-E	25I-NBOMe	3-MeO-2-Oxo-PCE
Methoxetamine	AM-2201 JWH-	x-MAPB	4,4' DMAR	LSZ	DOB
METHYLONE	BB-22 or	ALPHA-PVP	5-APB	Pentedrone	Methylone
DMT	DMT	MAM-2201	5F-AKB-48	Diphenidine	6 APB
DOC	JWH018	MDPV	5-MAPB	5-EAPB	
MPA	m-CPP	Pentedrone	5-MEO-DALT	5-MAPB	
AMT	STS-135	5F-AKB-48	ALPHA-PBP		
4,4' DMAR	UR-144	DOC	DMT		
4-MMC	x-	x-APDB	Étizolam		
5-APB		x-FA	FLUBROMAZEPAM		
5-EAPB		25C-NBOMe	JWH-073		
Hawaïen Baby		4-MMC	METHYLONE		
MBDB		Éthylone	MPA		
MDAI		JWH-073	PHENIBUT		
MDEA		JWH-081	PMMA		
Morning Glory		25I-NBOMe	PRIMIDONE		

TA = Toxicological analysis




National top list : choosing an aggregation method

Number of sources which list the substance		Average rank for at least twice listed substance		Number of sources with toxicological analysis with list the substance	
3-MMC	6	Methoxetamine	2,0	25C-NBOMe	3
4-MEC	6	Ethylphenidate	4,8	2C-E	3
25C-NBOMe	5	3-MMC	4,8	2C-P	3
2C-P	5	4-MEC	5,4	3-MMC	3
Ethylphenidate	5	BK-2CB	6,0	4-MEC	3
MDPV	5	2C-B	6,3	ALPHA-PVP	3
Methoxetamine	5	Mephedrone	7,5	DMT	3
Methylone	5	DMT	7,7	Ethylphenidate	3
25I-NBOMe	4	Methylone	7,8	KETAMINE	3
2C-E	4	Synthacaine	8,0	MDPV	3
ALPHA-PVP	4	MDPV	8,3	Methoxetamine	3
DMT	4	ALPHA-PVP	8,3	Methylone	3
MPA	4	2C-D	8,5	MPA	3
2C-B	3	x-EAPB	8,5	5F-AKB-48	2
2C-D	3	2C-E	8,7	25H-NBOMe	2
5F-AKB-48	3	MPA	9,7	25I-NBOMe	2
5-MAPB	3	25H-NBOMe	10,0	2C-B	2
DOC	3	25B-NBOMe	11,0	2C-C	2
25H-NBOMe	2	2-MEO-KETAMINE	11,0	2C-D	2
2C-C	2	4,4'DMAR	11,0	2C-I	2
4,4'DMAR	2	5-APB	11,0	2C-T-7	2
4-MMC	2	5-MEO-DALT	11,0	4,4'DMAR	2
5-APB	2	6-APB	11,0	4-HO-MET	2
5-EAPB	2	ALPHA-PBP	11,0	5-APB	2
6-APB	2	FLUBROMAZEPAM	11,0	5-MAPB	2



Aggregation at the European level

The I-TREND Top list



GB	Ban	The Netherlands	Ban	France	Ban	Poland	Ban	Czech Republic	Ban
5F-AKB48		MDPV	n	AM-2201	n	UR-144	n	3-MMC	n
4-MEC	y	4-MEC	n	UR-144	n	AM-2201	n	4-FA	n
MPA	y	3-MMC	n	MDPV	y	pentedrone	o	4-MEC	n
Ethylphenidate		25-I NBOME	n	4-MEC	y	3,4-DMMC	o	6-APB	n
AMT		5-(2-Aminopropyl)indole	n	25-I NBOME	n	Brephedrone	o	AMT	n
AM-2201		alpha-methyltryptamine	n	5-MEO-DALT	n	MPPP	n	methylone	y
AKB48		5-MEO-DALT	n	6-APB	n	MDPBP	n	ethcathinone	n
6-APB		6-APB	n	5-APB	n	PVP	o	MDPBP	n
Methylone	y	5-APB	n	Ethylphenidate	n	3-MMC	o	Methoxetamine	n
5-meo-dalt	y	Methoxetamine	n	Methoxetamine	y	ethcathinone	o	MPPP	y
Etizolam									
UR-144	y								
2-AI	y								
5-EAPB	y								
Methoxphendine									

Substances	Nb of countries
4-MEC 6-APB	4
3-MMC 5-meo-dalt AM-2201 Methoxetamine UR-144	3
25-I NBOME 5-APB AMT ethcathinone Ethylphenidate MDPBP MDPV Methylone MPPP	2


Concerns and questions

■ Selecting sources

- Restrict the number of sources but try to improve them
 - Customs seizures
 - Harm signals, toxicovigilance +++
 - General population survey or NPS users online surveys
 - Forum monitoring

■ Aggregating Top lists

- Elaborating a reasoned process to weight sources and aggregate lists
- Giving a place and time to qualitative expertise



Thank you for your attention

WWW.OFDT.fr

WWW.i-trend.eu

Agnes.cadet@ofdt.fr